There is no confirmation of anything right now except for a penny site releases possible merger news coming. There is a lot of focus on BMSN right now which to me entb has a much better share structure. But this was already posted but here is what the site sent out.
www.awesomepennypick.com merger news: not pennypick(s) Great email news. Somebody caught wind of it friday.
BMSN ~ Breaking Merger News is Pending.. The CEO of BMSN has mentioned its Pending to Announce Merger News with its Majority Owned Subsidiary Entest BioMedical, Inc (OTCBB: ENTB)..
Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of BMSN. The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), cancer immuno-therapies, testing procedures for diabetes and stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). Currently, Entest is focused on research and development in areas of COPD and Immuno-Therapeutic Cancer Vaccines. The Company sees applications for its patent pending technologies in both human and animal venues. Immuno-therapeutic treatment of cancer - The patent pending Entest application involves perfecting the use of cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses in treating cancer.
The treatment process itself will utilize an implantable encapsulation device as the vaccine delivery system and the initial focus will be treatment of cancer in canines. This canine cancer treatment may also provide clinical support for expansion into human cancer treatment. Chronic Obstructive Pulmonary Disease -There is currently no cure for COPD and therapy is limited to management of the condition and its symptoms. Over the next 5 years, it is estimated that over $170 BB will be spent on treating COPD in the United States. Entest believes its COPD treatment, which utilizes patent pending adult stem cell therapy coupled with photoceutical device enhancement, has the potential to reverse COPD related lung damage as well as alleviate symptoms. Entest BioMedical was founded for the purpose of providing excellence in biotechnology research (including adult stem cell regenerative treatment). Our objectives go beyond developing single products and procedures. Our mission is to discover and develop new procedures, treatments and medical devices that improve the quality of life. Our efforts revolve around a business focus of developing leading research and technology. Ongoing R&D is paramount to us in developing products and procedures with purpose, products and services that serve the present and help shape the future.
BMSN Shows a Monster Breakout coming now as well as the Company's 10K due out on January 15th so act fast on this one Members..
Make sure to Get ready tomorrow morning and pull up BMSN on your quotes and charts cause this one looks to run high short term..
AI
